Covagen enters into a strategic research collaboration and
license agreement with Mitsubishi Tanabe for the development of
bispecific FynomAbs.

ZURICH-SCHLIEREN, Switzerland, Oct. 17, 2012 – Covagen announced today that it has
entered into a strategic research collaboration and license agreement with Mitsubishi
Tanabe Pharma Corporation (Osaka, Japan) and its fully owned subsidiary Tanabe Research
Laboratories U.S.A., Inc. of San Diego Calif. (TRL). Under the agreement, Covagen will use
its proprietary Fynomer-antibody platform to generate bispecific proteins (FynomAbs)
against two target pairs selected by TRL and Mitsubishi Tanabe. Fynomers are small
binding proteins that can be engineered to bind to any antigen of interest. Because of their
excellent biophysical properties, Fynomers can be readily fused to therapeutic proteins
such as antibodies to create bispecific FynomAbs.

For the global, exclusive rights to bispecific FynomAbs against one target pair, Mitsubishi
Tanabe will pay to Covagen EUR 4.0 million upfront. Under the agreement, Mitsubishi
Tanabe will fund all research activities and be solely responsible for the development,
manufacturing and global commercialization activities. Upon achievement of certain
research, development and regulatory milestones, Covagen will be entitled to receive
payments of up to EUR 108.25 million for FynomAbs against the first target pair as well as
tiered royalties on worldwide net sales of products resulting from the collaboration.
Financial terms are substantially similar for FynomAbs addressing the second target pair
which TRL and Mitsubishi Tanabe have the option to select.

“This collaboration agreement is an important milestone for Covagen as we develop our
unique Fynomer technology and advance bispecific therapeutic FynomAbs in collaboration
and in our own therapeutic pipeline”, said Julian Bertschinger, Ph.D., chief executive officer
of Covagen. “Bispecific therapeutic compounds have enormous potential in the treatment
of many types of diseases and this collaboration is an important validation of our
pioneering work in this field.”
Dragan Grabulovski, Ph.D., chief scientific officer of Covagen, added: “This agreement
underlines the value of our FynomAb platform as a source of innovative bispecific biologics
with excellent biophysical properties and positions our company as a highly attractive
partner for the development of next generation biotherapeutics.”

Roland Newman, Ph.D., chief scientific officer of TRL, said: “This collaboration with
Covagen will allow TRL and Mitsubishi Tanabe to bring a new generation of biologics with novel mechanisms to physicians and their patients. We anticipate an exciting and fruitful
relationship with Covagen utilizing their bispecific FynomAb technology and their extensive
expertise in this area.”

About Covagen :
Covagen is a privately held company pioneering the commercialization of
Fynomers and bispecific Fynomer-antibody fusions (FynomAbs) as next generation protein
drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers are
small binding proteins that can be engineered to bind to any antigen of interest. Because
of their excellent biophysical properties, Fynomers can be readily fused to therapeutic
proteins such as antibodies to create bispecific FynomAbs. FynomAbs have novel modes of
action as they can engage simultaneously with multiple antigens or multiple binding sites
on the same target. At the same time, FynomAbs maintain the advantageous drug-like
properties of antibodies such as excellent stability and long half-life.

About Mitsubishi Tanabe Pharma Corporation :
Mitsubishi Tanabe Pharma Corporation is a
research-driven pharmaceutical company based in Osaka. Our philosophy states that “We
contribute to the healthier lives of people around the world through the creation of
pharmaceuticals.” In accordance with this philosophy, we strive to continually discover
drugs with new value and to provide those drugs to patients around the world. Mitsubishi
Tanabe Pharma is taking on the challenge of drug discovery in the fields of autoimmune
disorders, diabetes, and renal diseases, as well as in other fields with high levels of unmet
medical needs. To that end, the Company is strengthening its R&D pipeline.

About Tanabe Research Laboratories (TRL) :
TRL is an independent subsidiary of Mitsubishi
Tanabe Pharma Corporation located in San Diego California, whose role is to discover and
develop potential biological drug candidates for therapy. Currently, TRL’s efforts are
directed towards antibody and antibody related research to target specific immune cells
and/or soluble factors. TRL is establishing collaborative relationships with other companies
and academic research organizations to further its goals of identifying preclinical lead
compounds for therapeutic development.